ArticleClinical pharmacology and therapeutics2010

A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension.

M Gomberg-Maitland et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.